Truevis Technologies Targets ₹5,000 Crore Revenue with Indigenous Medical Equipment

Mumbai-based medtech startup Truevis Technologies is setting an ambitious goal of achieving ₹5,000 crore in revenue within the next five to six years. The company plans to achieve this by focusing on the indigenous manufacturing of critical medical equipment, including PET-CT scanners, LINAC (Linear Accelerator) machines, and MRI magnets. This strategic move aims to significantly reduce India’s dependence on imported medical devices and, consequently, lower the costs associated with cancer diagnosis and treatment.

The startup’s initiative is particularly significant in the context of India’s healthcare sector, which has long grappled with high import bills for advanced medical technologies. By developing and manufacturing these complex machines domestically, Truevis Technologies not only seeks to bolster the ‘Make in India’ initiative but also to make advanced diagnostic and therapeutic tools more accessible and affordable to a larger population. This could lead to earlier detection of diseases like cancer and more effective treatment outcomes.

The company’s focus on PET-CT, LINAC, and MRI magnets addresses key areas in oncology and advanced diagnostics. PET-CT scanners are crucial for detecting cancer at its earliest stages, while LINAC machines are vital for radiation therapy in cancer treatment. MRI magnets are the core component of MRI machines, essential for detailed imaging of soft tissues. The successful indigenous production of these items would represent a major leap forward for India’s medtech manufacturing capabilities.

Truevis Technologies’ vision extends beyond just revenue generation; it is deeply rooted in addressing systemic challenges within the Indian healthcare ecosystem. By cutting import dependence, the company aims to create a more resilient supply chain for essential medical equipment and contribute to a more self-reliant healthcare industry. Furthermore, the anticipated reduction in costs for diagnosis and treatment could have a profound positive impact on patient access and affordability, particularly for cancer care.